US Study Finds Pfizer-BioNTech, Moderna Covid-19 Vaccines Effective In Real World Conditions

A new study has said that Pfizer and Moderna’s Covid-19 vaccines help prevent the spread of the virus. The study was conducted by the US Centers for Disease Control and Prevention. It said that the two vaccines are highly effective in containing infection in real-world conditions. The CDC study said that the risk of contracting infection was reduced by 90 percent after the second dose. The second dose is administered after a gap of two or more weeks. After the first dose, the risk of infection was reduced by 80 percent. The study involved 4,000 participants in six US states. Researchers studied the effectiveness of Pfizer-BioNTech and Moderna mRNA vaccines for 13 weeks. The study was conducted between December last year and March 2021.

The study said that the body produced antibodies to protest against coronavirus after two weeks of inoculation of each dose. The findings are in line with the data obtained during the phase 3 clinical trials of the drugs. The FDA has granted emergency use authorizations to the two vaccines. The drugs are being currently administered to people in the United States. The CDC said that clinical trials of vaccines evaluated their efficacy against disease. But the latest study was conducted to evaluate their effectiveness against the infections. This included infections that have no symptoms. The CDC said that the government’s national vaccination program is working and producing desired results. The two are mRNA vaccines.

The latest study has also provided insight into partial vaccination. Past studies conducted in the UK and Israel said that one dose of Pfizer-BioNTech vaccine was 70 percent effective and Moderna was 60 percent against infection. The data gives reassurance of the fact that vaccines are effective and people start to develop antibodies after inoculation. The study concluded that the greatest protection was seen in participants who have received both doses. The two vaccines are being authorized for use in individuals above 16 years. The CDC in another report said that nearly everyone in the US who got their first dose received their second dose within the recommended timeframe.

Kathleen Kinder

With over four years of experience in the research industry, Kathleen is generally engrossed in market consulting projects, catering primarily to domains such as ICT, Health & Pharma, and packaging. She is highly proficient in managing both B2C and B2B projects, with an emphasis on consumer preference analysis, key executive interviews, etc. When Kathleen isn’t deconstructing market performance trajectories, she can be found hanging out with her pet cat ‘Sniffles’.